Increased serum insulin-like growth factor-1 levels are associated with prolonged response to dasatinib-based regimens in metastatic prostate cancer

Prostate

Volumn 73, Issue 9, 2013, Pages 979-985

  Dayyani, Farshid ^a   Varkaris, Andreas ^a   Araujo, John C ^a   Song, Jian H ^a   Chatterji, Tanushree ^a,b   Trudel, Geralyn C ^c   Logothetis, Christopher J ^a   Gallick, Gary E ^a,b  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b UNIVERSITY OF TEXAS   (United States)

^c BRISTOL MYERS SQUIBB   (United States)

Author keywords

bone microenvironment; docetaxel; predictive marker; Src inhibition; xenograft

Indexed keywords

1 [4 [(5 CYCLOPROPYL 1H PYRAZOL 3 YL)AMINO]PYRROLO[2,1 F][1,2,4]TRIAZIN 2 YL] N (6 FLUORO 3 PYRIDINYL) 2 METHYL 2 PYRROLIDINECARBOXAMIDE; DASATINIB; DOCETAXEL; SOMATOMEDIN C;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD LEVEL; CASTRATION RESISTANT PROSTATE CANCER; CELL DIFFERENTIATION; CELL INTERACTION; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HUMAN CELL; MALE; METASTASIS; MOUSE; NONHUMAN; OSTEOBLAST; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN INDUCTION; PROTEIN SECRETION; TREATMENT DURATION; TREATMENT RESPONSE; TUMOR CELL; TUMOR MICROENVIRONMENT; TUMOR XENOGRAFT;

3T3 CELLS; ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CELL LINE, TUMOR; CLINICAL TRIALS, PHASE I AS TOPIC; CLINICAL TRIALS, PHASE II AS TOPIC; ENZYME-LINKED IMMUNOSORBENT ASSAY; HUMANS; INSULIN-LIKE GROWTH FACTOR I; MALE; MICE; MICE, NUDE; NEOPLASMS, HORMONE-DEPENDENT; OSTEOBLASTS; PROSTATIC NEOPLASMS; PYRIMIDINES; TAXOIDS; THIAZOLES; TUMOR MARKERS, BIOLOGICAL; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84878299480     PISSN: 02704137     EISSN: 10970045     Source Type: Journal    
DOI: 10.1002/pros.22645     Document Type: Article

References (25)

1. Dayyani F, Gallick GE, Logothetis CJ, Corn PG,. Novel therapies for metastatic castrate-resistant prostate cancer. J Natl Cancer Inst 2011; 103: 1665-1675.
2. Loberg RD, Logothetis CJ, Keller ET, Pienta KJ,. Pathogenesis and treatment of prostate cancer bone metastases: Targeting the lethal phenotype. J Clin Oncol 2005; 23: 8232-8241.
3. Park SI, Zhang J, Phillips KA, Araujo JC, Najjar AM, Volgin AY, Gelovani JG, Kim SJ, Wang Z, Gallick GE,. Targeting SRC family kinases inhibits growth and lymph node metastases of prostate cancer in an orthotopic nude mouse model. Cancer Res 2008; 68: 3323-3333.
4. Summy JM, Gallick GE,. Src family kinases in tumor progression and metastasis. Cancer Metastasis Rev 2003; 22: 337-358.
5. Lee YC, Huang CF, Murshed M, Chu K, Araujo JC, Ye X, deCrombrugghe B, Yu-Lee LY, Gallick GE, Lin SH,. Src family kinase/abl inhibitor dasatinib suppresses proliferation and enhances differentiation of osteoblasts. Oncogene 2010; 29: 3196-3207.
6. Araujo JC, Mathew P, Armstrong AJ, Braud EL, Posadas E, Lonberg M, Gallick GE, Trudel GC, Paliwal P, Agrawal S, Logothetis CJ,. Dasatinib combined with docetaxel for castration-resistant prostate cancer: Results from a phase 1-2 study. Cancer 2012; 118: 63-71.
7. Dayyani F, Parikh NU, Varkaris AS, Song JH, Moorthy S, Chatterji T, Maity SN, Wolfe AR, Carboni JM, Gottardis MM, Logothetis CJ, Gallick GE,. Combined inhibition of IGF-1R/IR and Src family kinases enhances antitumor effects in prostate cancer by decreasing activated survival pathways. PloS one 2012; 7 (12): e51189.
8. Furstenberger G, Senn HJ,. Insulin-like growth factors and cancer. Lancet Oncol 2002; 3: 298-302.
9. Gennigens C, Menetrier-Caux C, Droz JP,. Insulin-like growth factor (IGF) family and prostate cancer. Crit Rev Oncol Hematol 2006; 58: 124-145.
10. Papatsoris AG, Karamouzis MV, Papavassiliou AG,. Novel insights into the implication of the IGF-1 network in prostate cancer. Trends Mol Med 2005; 11: 52-55.
11. Roberts CT Jr., IGF-1 and prostate cancer. Novartis Found Symp 262: 2004; 193-199; discussion 199-204, 265-198.
12. Wu JD, Haugk K, Woodke L, Nelson P, Coleman I, Plymate SR,. Interaction of IGF signaling and the androgen receptor in prostate cancer progression. J Cell Biochem 2006; 99: 392-401.
13. Chan JM, Stampfer MJ, Giovannucci E, Gann PH, Ma J, Wilkinson P, Hennekens CH, Pollak M,. Plasma insulin-like growth factor-I and prostate cancer risk: A prospective study. Science 1998; 279: 563-566.
14. Chan JM, Stampfer MJ, Ma J, Gann P, Gaziano JM, Pollak M, Giovannucci E,. Insulin-like growth factor-I (IGF-I) and IGF binding protein-3 as predictors of advanced-stage prostate cancer. J Natl Cancer Inst 2002; 94: 1099-1106.
15. Lin HK, Yeh S, Kang HY, Chang C,. Akt suppresses androgen-induced apoptosis by phosphorylating and inhibiting androgen receptor. Proc Natl Acad Sci USA 2001; 98: 7200-7205.
16. Plymate SR, Tennant MK, Culp SH, Woodke L, Marcelli M, Colman I, Nelson PS, Carroll JM, Roberts CT Jr, Ware JL,. Androgen receptor (AR) expression in AR-negative prostate cancer cells results in differential effects of DHT and IGF-I on proliferation and AR activity between localized and metastatic tumors. Prostate 2004; 61: 276-290.
17. Mohan S, Baylink DJ,. Bone growth factors. Clin Orthop Relat Res 1991; 263: 30-48.
18. Kim SJ, Uehara H, Yazici S, Busby JE, Nakamura T, He J, Maya M, Logothetis C, Mathew P, Wang X, Do KA, Fan D, Fidler IJ,. Targeting platelet-derived growth factor receptor on endothelial cells of multidrug-resistant prostate cancer. J Natl Cancer Inst 2006; 98: 783-793.
19. Fabbri F, Brigliadori G, Carloni S, Ulivi P, Tesei A, Silvestrini R, Amadori D, Zoli W,. Docetaxel-ST1481 sequence exerts a potent cytotoxic activity on hormone-resistant prostate cancer cells by reducing drug resistance-related gene expression. Prostate 2010; 70: 219-227.
20. O'Brien MF, Watson RW, Fitzpatrick JM,. Insulin-like growth factor I and prostate cancer. Urology 2001; 58: 1-7.
21. Pollak M, Beamer W, Zhang JC,. Insulin-like growth factors and prostate cancer. Cancer Metastasis Rev 1998; 17: 383-390.
22. Ohlsson C, Mohan S, Sjogren K, Tivesten A, Isgaard J, Isaksson O, Jansson JO, Svensson J,. The role of liver-derived insulin-like growth factor-I. Endocr Rev 2009; 30: 494-535.
23. Yu EY, Massard C, Gross ME, Carducci MA, Culine S, Hudes G, Posadas EM, Sternberg CN, Wilding G, Trudel GC, Paliwal P, Fizazi K,. Once-daily dasatinib: Expansion of phase II study evaluating safety and efficacy of dasatinib in patients with metastatic castration-resistant prostate cancer. Urology 2011; 77: 1166-1171.
24. Yu EY, Wilding G, Posadas E, Gross M, Culine S, Massard C, Morris MJ, Hudes G, Calabro F, Cheng S, Trudel GC, Paliwal P, Sternberg CN,. Phase II study of dasatinib in patients with metastatic castration-resistant prostate cancer. Clin Cancer Res 2009; 15: 7421-7428.
25. Montero JC, Seoane S, Ocana A, Pandiella A,. Inhibition of SRC family kinases and receptor tyrosine kinases by dasatinib: Possible combinations in solid tumors. Clin Cancer Res 2011; 17: 5546-5552.